To learn more about Angelman syndrome, connect with others in the community, and find resources to help you navigate a diagnosis, please visit the following links.
Learn more about clinical trials: STARS and ELARA
Frequently Asked Questions
Ovid Therapeutics is currently developing a potential treatment option for Angelman syndrome. To learn more about our clinical trials, please visit our website.
No. The investigational medicine and care required by Ovid’s studies will be provided at no expense. You will also be reimbursed for travel-related expenses.
Ovid is committed to developing potential therapies for those with Angelman syndrome and other neurological conditions. We look forward to providing updates to the community about our Angelman syndrome program and future clinical studies. Visit our website and follow our social channels for the latest news.
Half of individuals with Angelman syndrome are originally misdiagnosed.1 In most cases, a blood test identifies whether the UBE3A gene is functioning properly, however 15-20% of individuals require observation by an experienced clinician who is familiar with Angelman syndrome.1 To find a clinician in your area, contact the ASF.
“Biotech innovation means creating a collaborative and compliant standard of face-to-face interaction with patients. This thinking is not patient-centric, it is human-centric.”
Associate Director of Patient Engagement, Ovid Therapeutics
For clinical and scientific questions about Ovid’s experimental therapies, please contact firstname.lastname@example.org.
1. ASF Diagnosis. https://www.angelman.org/what-is-as/diagnosis/. Accessed June 14, 2018.